Skip to Primary Navigation

Skip to main content

Medicare drug pricing plan could depend on limited international data

A photo of a poster listing drug reduction information
Photo: Andrew Harnik/Getty Images

Kevin Kinsella

2 min read
Click to share on Facebook (Opens in new window/tab) Click to share on X (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

A new study found proposed Medicare drug pricing models may rely on prices from relatively few international markets.

A proposed Medicare drug pricing policy that ties reimbursement to international prices could face challenges because many new drugs are not launched broadly in comparable countries soon after US approval, according to a new cross-sectional study published on JAMA Health Forum.

Researchers analyzed 79 single-source drugs and biologics approved byGlobal

, , , , , ,

Get full access, free for a month

This is a Premium article. Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

Start free trial Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience